RT  - European Journal of Gynaecological Oncology
ID  - 10.12892/ejgo3322.2017
T1  - Short-term curative effect and safety of bevacizumab combined with chemotherapy for treating recurrent and metastatic cervical cancer
A1  - Y. Xiao
A1  - H.J. Cheng
A1  - L. Wang
A1  - S.X. Luo
K1  - Cervical neoplasms; Bevacizumab
K1  - Drug therapy
K1  - Targeted therapy
K1  - Drug toxicity.
YR  - 2017
SP  - 76
AB  - <p><i>Objective: </i>To observe bevacizumab plus chemotherapy curative effect and safety for recurrent and metastatic cervical cancer. <i>Materials and Methods: </i>Retrospective analysis of 30 recurrent and metastatic cervical cancer cases. The experimental group received bevacizumab plus paclitaxel-, docetaxel-, and platinum-based chemotherapy. The control group received only chemotherapy. Curative effects were recorded after at least two treatment cycles; adverse reactions were recorded with every cycle. <i>Results: </i>Experimental group patients were treated for an average 2.6 cycles. Compared to the control group, the experimental group effective rate (26.7%) was similar, disease control rate (73.7%) was significantly higher, and median survival time was three months longer. Bevacizumab-associated adverse reactions were bleeding, hypertension, and thrombosis/embolism; most were level 1 and 2 reactions. Adverse reactions in the two groups were not statistically different. <i>Conclusions: </i>The bevacizumab plus chemotherapy disease control rate for recurrent and metastatic cervical cancer is comparatively high, prolonging median survival; bevacizumab-associated adverse reactions are mild and tolerable.</p>